Regarding the use of IL-17 and IL-23 inhibitors and TB, evidence to date indicates that they do not increase the risk of TB reactivation, and these two interleukins are probably not essential in the pathogenesis of immune response against Mtb [57]. This evidence concerns the gene IL17A and tuberculosis.